

eatris 10 **YEAR** ANNIVERSARY CONFERENCE

21-22 Nov 2023

The Hague, the Netherlands

#EATRIS10

Programme

TUESDAY 21 NOVEMBER 2023

INTERNATIONAL CONFERENCE AT MUSEON-OMNIVERSUM, THE HAGUE, THE NETHERLANDS

- **1400-1430** Registration, doors open and welcome coffee
- **1430-1440** Welcome address - ‘Celebrating Translational Research’ by [Toni Andreu](#) (EATRIS Scientific Director)
- **1440-1510** Keynote - [Claudia Maria Coelho de Faria](#) (Biobanco-iMM Founder and Co-director, Chair of Board of National Directors & National Director of Portugal)
- **1510-1540** Group Photo, Pause and Refill moment
- **1540-1550** EATRIS community perspective by [Jelena Ilić-Dreven](#) (Co-Chair of the EATRIS Board of Governors; Directorate for Science and Technology, Ministry of Science and Education, Republic of Croatia)
- **1550-1600** Speech from Ernst Kuipers (Minister of Health, Welfare and Sport of the Netherlands)
- **1600-1710** Roundtable discussion about “Challenges and opportunities for translational medicine in Europe”, moderated by [Anton Ussi](#) (EATRIS Operations & Finance Director), with:
 - [Manuela Cirilli](#) (CERN Medical Applications Advisor)
 - [Hans van Goudoever](#) (Dean of Medicine University of Amsterdam and Vice-Chairman of Amsterdam UMC)
 - [Ernst Kuipers](#) (Minister of Health, Welfare and Sport of the Netherlands)
 - [Don Lo](#) (EATRIS Director of Medicines Development)
 - [Maurice Whelan](#) (Head of the Systems Toxicology Unit and ECVAM, European Commission, Joint Research Centre)
- **1710-1715** Closing remarks by [Anton Ussi](#) (EATRIS Operations & Finance Director)

DINNER OF THE DECADE & ENTERTAINMENT AT KUNSTMUSEUM, THE HAGUE, THE NETHERLANDS

***DRESS CODE:** There is no strict dress code so please feel free to dress as you wish. However, we kindly suggest that you consider dressing in something that reflects the significance of the occasion.*

- **1900-2000** Drinks reception and optional exclusive private Kunstmuseum tour
 - **2000-2130** Seated dinner in the Kunstmuseum Garden Gallery with speeches and awards
 - **2130-0000** Walking dessert, drinks and live music
- All evening** Photo booth and “EATRIS 10 Year Timeline” installation wall

Underlined text in this programme serves as a hyperlink, providing you with direct access to additional information and resources. Simply click on the underlined text to explore further details.

WEDNESDAY 22 NOVEMBER 2023

INTERNATIONAL CONFERENCE AT MUSEON-OMNIVERSUM, THE HAGUE, THE NETHERLANDS

- **0830-0900** Welcome coffee
- **0900-1015** “Patient Engagement: the New Normal” session

This session will address why and how patients should be embedded in translational research, and what the added value of patient engagement is. It will highlight how patient advocates and academic researchers are already making patient engagement the new normal and look at ways to make further progress in this area of responsible research.

0900-0920 Keynote “The Power of Patient Voice” from Chloe Joyner (Founder of Usher Kids UK)

0920-1015 Roundtable discussion, moderated by Maria Duterte (EUPATI Executive Director of the European Patients’ Academy), with:

- Valery Dassen (Brain Foundation Programme manager, Research and Innovation)
- Monika Frenzel (International coordinator, French National Research Agency and European Partnership for Personalised Medicine)
- Stan van de Graaf (Professor in Experimental Hepatology and Metabolism of the Amsterdam UMC; Head of the Tytgat Institute for Liver and Intestinal Research)
- Larissa de Lannoy (Patient Advocate)
- Valentina Strammiello (European Patients’ Forum Director of Programmes)

- **1015-1045** Coffee break
- **1045-1200** “Bridging the Innovation Gap” Session

This session will explore effective multistakeholder collaboration to cross the valley of death. How are the bridges holding today? It will look at how researchers and funders can work together to enhance the translational feasibility of research plans (robustness, quality and rigor of research, path to market, exploitation potential, patient impact). It will cover systemic bottlenecks, policy, legislation (HTA and regulatory), incentives and sustainable solutions for innovators and researchers. It will also look at (ultra) rare diseases as a driver for innovation and future direction and opportunities under the European Joint Programme on Rare Diseases (EJP RD).

1045-1105 Keynote “Building a translational ecosystem” from Christopher Baum (Chairman of the Board of Directors of the BIH at Charité and Chief Translational Research Officer of Charité-Universitätsmedizin Berlin)

1105-1200 Roundtable discussion, co-moderated by Montserrat Daban (Biocat Director of Strategic Foresight and International Relations; Council European BioRegions President; EIT Health Innostars Mentor and Evaluator; European Clusters Alliance Board Member) and Martin de Kort (EATRIS Senior Scientific Programme Manager), with:

- Corne Baatenburg de Jong (ReumaNederland Adjunct Director)

- [Daria Julkowska](#) (EJP RD Scientific Coordinator)
- [Cecile Ollivier](#) (C-Path Europe Managing Director)
- [Lars Schlotawa](#) (Consultant for paediatrics, child neurology and metabolic medicine at the University Medical Centre Goettingen)

- **1200-1330** Lunch

- **1330-1445** “Personalised medicine – the future is now” Session

While Personalised Medicine is quickly progressing it has yet to fully make its way to the clinic. The journey from scientific discovery to the implementation of novel solutions in the healthcare domain where all stakeholders involved collaborate remains uncertain. This session will explore the key milestones and challenges encountered on this path, bringing together experts to discuss the tools required to create an inclusive approach for long-term systemic change. Will academia, industry, healthcare providers, payers and regulators be able to provide the most suitable medicine for each individual – to the right person, at the right dose, and at the right time? Are we culturally prepared for reshaping processes for the widespread implementation of Personalised Medicine? Join us to discuss whether we can turn the promise of Personalised Medicine into a reality.

1330-1350 Keynote from [Ivo G. Gut](#) (Director of Centro Nacional de Analisis Genomico, Barcelona)

1350-1445 Roundtable discussion, moderated by [Toni Andreu](#) (EATRIS Scientific Director) with:

- [Claudia Maria Coelho de Faria](#) (Biobanco-iMM Founder and Co-director, Chair of Board of National Directors & National Director of Portugal)
- [Ewa Ellis](#) (Laboratory director of the liver cell laboratory at the unit for transplantation surgery, Karolinska Institutet; President of the Cell Transplant and Regenerative Medicine Society, under TTS)
- [Alain van Gool](#) (Professor Personalized Healthcare at the Radboud University Medical Center; EATRIS-Plus representative)
- [Fátima Núñez](#) (Deputy Director of Research, Innovation and Knowledge Management at Hospital Sant Joan de Deu Barcelona)
- [Astrid Vicente](#) (Head of Department of Health Promotion and NCD Prevention; Senior Researcher; Associate Professor at the Faculty of Sciences, University of Lisbon)

- **1445-1500** Final Remarks and adjourn from [Anton Ussi](#) (EATRIS Operations & Finance Director) and [Toni Andreu](#) (EATRIS Scientific Director)

SPEAKERS

Toni Andreu, EATRIS Scientific Director



Toni Andreu is the EATRIS Scientific Director. He is an M.D. Ph.D specialised in genetics and genomics of rare diseases. Toni has been working in the field of neuromuscular disorders from the translational perspective of the pipeline, from basic science to the development of cell and animal models and clinical research. After working in Columbia University in New York on mitochondrial disorders from 1998 to 2001, he moved to Barcelona to create the Neuromuscular Lab at the Vall d'Hebron Research Institute where he became Director of the Neurosciences Research Programme. He has also been extremely active in the field of policy-making, and held positions as the Director of the Spanish National Institute of Health Carlos III, as well as the Director General for Research and Innovation at the Catalan Ministry of Health.

Anton Ussi, EATRIS Operations & Finance Director



Anton Ussi is the EATRIS Operations & Finance Director. Joining EATRIS in 2010, he was co-responsible for the operational design and statutory incorporation of the infrastructure, and has been in his current role since 2015. With a background in mechanical engineering in the automotive industry, small business administration, and later in technology transfer focused on molecular imaging, Ussi specialises in public private collaboration and deployment of infrastructure for translational research in medicine.

Claudia Maria Coelho de Faria, Biobanco-iMM Founder and Co-director, Chair of Board of National Directors & National Director of Portugal



Claudia Maria Coelho de Faria received her MD from the University of Coimbra in 2001. She did her training in the Department of Neurosurgery at Hospital de Santa Maria – Centro Hospitalar Universitário Lisboa Norte and became a board-certified neurosurgeon in 2010. With her interest in the genetics of brain tumours, particularly in the paediatric population, she did her PhD at the Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children (Canada) with Prof Rutka. Using the genetic signatures of medulloblastoma, she studied the mechanisms of tumour recurrence and dissemination and identified novel small molecule inhibitors that were successfully tested in preclinical models of the disease. Upon returning to Lisbon in 2014, Claudia Faria became a clinician-scientist working as a Consultant Neurosurgeon at CHULN, as a researcher at Instituto de Medicina Molecular João Lobo Antunes and as an Invited Assistant Professor of Neurosurgery and Neurology at Faculdade de Medicina da Universidade de Lisboa. She founded the Brain Tumor Bank at Biobanco-iMM in 2012 and became co-director of Biobanco-iMM in 2018, being responsible to supervise and coordinate the activities of scientific and technical committees, to foster the collaboration between medical doctors and researchers and to promote dissemination and fundraising actions for scientific research. Since 2018 she is the Portuguese representative in the Board of National Directors of EATRIS and in November 2020 she was elected chair of the Board of National Directors.

Jelena Ilić-Dreven (Co-Chair of the EATRIS Board of Governors; Directorate for Science and Technology, Ministry of Science and Education, Republic of Croatia)



Jelena Ilić-Dreven has been working at the Croatian Ministry of Science and Education for seven years. She is Head of Department for Scientific and Technological Policies. Jelena is Croatia's representative in some of the most important EU's bodies like: European Strategy Forum on Research Infrastructures (ESFRI), European Research Area

and Innovation Committee (ERAC) and European Research Area Forum. She is national coordinator for EU research infrastructure and is actively involved as national representative in EATRIS ERIC, SHARE ERIC, CESSDA ERIC and future CTAO ERIC.



Manuela Cirilli, CERN Medical Applications Advisor

Manuela Cirilli works at CERN, the European Laboratory for Particle Physics. She is currently Medical Applications Adviser and Head of Communication, Marketing and Training in CERN's Knowledge Transfer group, as well as Chair of CERN's Medical Applications Project Forum. Prior to joining CERN's Knowledge Transfer group in 2010, Manuela was an experimental researcher in particle physics. She has extensive experience in detector construction and commissioning, data analysis, and databases, and has held several coordination roles in both the NA48 and ATLAS Collaborations at CERN. Manuela holds a PhD in Particle Physics from the "Scuola Normale Superiore" in Pisa, Italy, as well as a Master in Science Communication and Journalism from the University of Ferrara, Italy. In parallel to her scientific career, Manuela has been engaging in science communication and popularisation since the early 2000s. She is also actively involved in promoting diversity and inclusion in STEM, with particular attention to gender and neurodiversity.



Hans B. van Goudoever, Dean of Medicine University of Amsterdam and Vice-Chairman of Amsterdam UMC

Hans van Goudoever is Dean of the Faculty of Medicine of the University of Amsterdam and Vice-Chair of Amsterdam University Medical Centers since 2022. On 1st November 2023 he became Chair of Amsterdam University Medical Centers. Hans is a professor of Pediatrics at the University of Amsterdam and the Free University. He performed research for his PhD on Nitrogen metabolism in preterm infants. Subsequently, he worked at the Clinical Nutrition Research Center, Texas Children's, Baylor College of Medicine, Houston, TX, USA, and at The Erasmus University of Rotterdam, mostly on intermediary metabolism. He was trained as a neonatologist and became professor and chair of neonatology in 2004. He has served in many international councils and is appointed by his royal majesty as a member of the national Health Council from 2014 onwards. He has published approximately 450 peer reviewed articles and 30 book chapters predominantly on neonatal nutrition and metabolism.



Ernst Kuipers, Minister of Health, Welfare and Sport of the Netherlands

Ernst Kuipers, the Dutch Minister of Health, Welfare, and Sport in the fourth Rutte government, is a prominent figure in healthcare and medicine. With a background in chemistry and medicine from the University of Groningen, he specialises in internal medicine and gastroenterology, earning a doctorate with distinction for his work on *Helicobacter pylori*, chronic gastritis, and gastric cancer. Kuipers held influential positions at Erasmus Medical Centre, including Professor and Head of Gastroenterology. He chaired medical clusters and served on the boards of healthcare organisations. His commitment to healthcare extends globally with roles in Singapore's National University Health System and leadership in national acute care networks.



Don Lo, EATRIS Director of Medicines Development

Don is the Director for Medicines Development at EATRIS and Scientific Lead of the REMEDI4ALL European Platform for Medicines Repurposing. Don previously headed therapeutic development at the National Center for Advancing Translational Sciences at the US National Institutes of Health following a 30-year career in academia, biotech, non-disease research foundations and patient care organisations.



Maurice Whelan, Head of the Systems Toxicology Unit and ECVAM, European Commission, Joint Research Centre (JRC)

Prof. Maurice Whelan is Deputy Director of the Directorate for Health and Food of the European Commission's Joint Research Centre (JRC) based in Italy, and head of its Systems Toxicology Unit. He also heads the JRC's EU Reference Laboratory for alternatives to animal testing, better known as ECVAM. Maurice is the EU co-chair of the OECD Advisory Group on Emerging Science for Chemicals Assessment (ESCA); a member of the Steering Committee of the European Partnership for Alternative Approaches to Animal Testing (EPAA); and chair of the Regulatory Advisory Board of the European Organ-on-Chip Society (EUROoCS). His publications include over 200 scientific papers and a book on the validation of alternative methods for toxicity testing. He has held a number of external appointments including the 2017-2018 Francqui Chair for alternative methods at the Vrije Universiteit Brussel (VUB, Belgium), and is currently visiting Professor of Bioengineering at the University of Liverpool (UK).



Chloe Joyner, Founder of Usher Kids UK

Chloe Joyner founded Usher Kids UK in 2017, in response to gaps in support and information following her child's diagnosis of Usher syndrome, a rare cause of progressive deafblindness. Usher Kids UK now serves over 400 families in the UK and beyond, empowering the next generation living with this condition, by giving access to the tools, resources and connections they need to thrive. Chloe is passionate about increasing cross-sector collaboration which utilises insights from the patient community to accelerate progress towards improved outcomes for those living with rare conditions.



Maria Dutarte, EUPATI Executive Director of the European Patients' Academy

Maria Dutarte is the Executive Director of the European Patients' Academy (EUPATI) since 2020. Maria has previously worked for the European AIDS Treatment Group (EATG) coordinating patient involvement in a number of training initiatives and scientific projects. She has also worked for different scientific and international organisations, e.g. French National Research Center for Scientific Research (CNRS), International AIDS Society (IAS), The Global Fund to Fight AIDS, Tuberculosis and Malaria and The International Foundation for Science (IFS). Her educational background is in International Education and Communications.



Valery Dassen, Brain Foundation Programme manager, Research and Innovation.

Valery Dassen, a dedicated advocate for accessible brain health solutions. With a background in Psychology and Cellular Neuroscience, Valery has been working at the Brain Foundation Netherlands for 4.5 years, focused on funding research to develop and improve treatments for brain disorders. In this role she actively supports the

foundation's transformation from a traditional funder wielding the 'fund and forget principle', to a proactive facilitator trying to get research outcomes one step closer to the patient.



Monika Frenzel, International coordinator, French National Research Agency and European Partnership for Personalised Medicine

Dr Monika Frenzel, International Coordinator in the Biology and Health department of the French National Research Agency (L'Agence Nationale de la Recherche, ANR), represents ANR in several transnational collaborations and international funding programmes, particularly in the field of Personalised Medicine, i.e. the International Consortium for Personalised Medicine, ICPeMed and the Coordination and Support Action (CSA) EU-Africa PerMed "Building Links Between Europe and Africa in Personalised Medicine". Dr Monika Frenzel was highly involved in the preparations of the European Partnership for Personalised Medicine, EP PerMed, notably as co-lead of the Drafting Group (development of the Draft proposal of the EP PerMed and the Strategic Research and Innovation Agenda for Personalised Medicine, SRIA for PM, 2023) and the Writing Group (EP PerMed proposal development). In the EP PerMed, she is leading the Work Package 2 on "Personalised Medicine Research-related Funding and Support". Monika Frenzel completed her PhD in Physical Biochemistry and Radiation Biology and worked as researcher in the field of cytogenetics and cohort studies.



Stan van de Graaf, Professor in Experimental Hepatology and Metabolism of the Amsterdam UMC; Head of the Tytgat Institute for Liver and Intestinal Research

Stan van de Graaf is Professor in Experimental Hepatology and Metabolism of the Amsterdam University Medical Centers (the Netherlands) and head of the Tytgat Institute for Liver and Intestinal Research housing ~70 investigators. He is also co-director of the research institute Amsterdam Gastroenterology, Endocrinology and Metabolism with ~95 Principal Investigators. He is recipient of an European Research Council Starting grant, the UEG Rising Star Award in 2018 and Dutch VENI, VIDI and VICI grant laureate. His main research interests are bile flow and metabolic processes in liver, with a focus on transport and signalling processes.



Larissa de Lannoy, Patient Advocate

Larissa de Lannoy is a currently independent Patient Advocate with experience in the field of Inflammatory Bowel Disease (IBD) and Primary Sclerosing Cholangitis (PSC) and generally in the field of rare disease and drug development. She holds a BSc in Biopharmaceutical Sciences and a PhD in Pharmacology. She worked over 20 years within the Pharmaceutical Industry for several companies (Organon, Eli Lilly, Astellas and Johnson&Johnson) within the field of Regulatory Affairs, building regulatory strategies with the R&D teams in drug development. As Patient Advocate she was trained by Eurordis. Her Patient Advocacy work mainly focuses on Science, R&D and Regulatory Science. She was a former board member of the PSC Patients Europe organization. She is a member of the Advisory Committee of Regulatory Science Network Netherlands and the Patient&Public Advisory Committee of Health-RI. Her work as Patient Advocate varies from bringing the voice of the patients to workshops, round table discussions and expert meetings related to strategic health care topics or regulatory science related topics. Her mission is to help pave the way for new treatments, innovative health care solutions and use of data.



Valentina Strammiello, European Patients Forum (EPF) Director of Programmes

Valentina Strammiello has been working at the European Patients Forum (EPF) for the past ten years. She is currently the Director of Programmes and oversees the EPF project portfolio and activities in the area of Health Technology Assessment and Patient Engagement. Before joining EPF, Valentina worked as freelance OSINT analyst on Security and Energy issues. Self-trained in website management and web 2.0 applications, she is among the founders of ecpa2.0 (European Centre for Public Affairs 2.0), a forum of young professionals in Public Affairs. She holds Master degrees in International Relations and European Studies.



Christopher Baum, Chairman of the Board of Directors of the BIH at Charité and Chief Translational Research Officer of Charité-Universitätsmedizin Berlin

Professor Christopher Baum studied philosophy in Mainz, and medicine in Essen, Freiburg and Hamburg. He obtained his doctorate in 1991, and qualified as a professor in the field of molecular medicine in 1999 at the University of Hamburg. In 2000, he joined the Hannover Medical School (MHH) as a professor for stem cell biology, and was also an associate professor of pediatrics at the Cincinnati Children's Hospital in the United States from 2002. In Hanover, he led the Institute of Experimental Hematology from 2006 and served as both the Ombudsperson for Good Scientific Practice and the Dean of Research. He was elected President of the MHH in 2013. At the beginning of 2019, Baum moved to the University of Lübeck as its first full-time Vice President for Medicine and a member of the Board of Directors of UKSH – Germany's second largest university hospital after Charité. In October 2020, Christopher Baum became Chairman of the Board of Directors of the Berlin Institute of Health (BIH), and since the integration of BIH into Charité, he has been Chair of the BIH Board of Directors and Chief Translational Research Officer of Charité – Universitätsmedizin Berlin.



Montserrat Daban, Biocat Director of Strategic Foresight and International Relations; Council European BioRegions President; EIT Health Innostars Mentor and Evaluator; European Clusters Alliance Board Member

Montserrat has a degree in Biology, a doctorate in Molecular Biology and masters in Scientific Communication with a focus on Medicine, and in Diplomacy and Foreign Relations. She has worked as a researcher in life sciences and scientific communication in Barcelona, Lille (France) and Cleveland (OH, USA). Her experience also includes advice on R+D+ii International Relations policies for the Department of Research and Universities of the Generalitat de Catalunya, in addition to her work as scientific editor at Editorial Rubes. Since 2006, Montserrat has held various positions at Biocat, addressing areas that include Communication, Scientific Policy and International Relations. Currently, she also serves as president of the Council of European BioRegions (CEBR). Montserrat is fluent in five languages, including Catalan, Spanish, English, French and Italian. Her interests span a wide range of areas, including communication, strategy, ecosystems, innovation, internationalisation, gender, open science, impact assessment, dual transformation, digitisation and collaboration.



Martin de Kort, EATRIS Senior Scientific Programme Manager

Martin obtained his PhD in bio-organic chemistry at Leiden University, The Netherlands in 2000. He then joined Organon to work on synthetic heparin conjugates for the treatment of thrombosis (one drug reached Phase II). From 2007, he worked as a lead optimisation project manager at Schering-Plough to develop antidiabetic peptides (e.g. novel insulin and incretins). After the merge with Merck in 2009 he co-headed

multidisciplinary teams at MSD involved in lead optimisation of small molecules in endocrinology and development of therapeutic biologicals with prolonged duration of action using proprietary technology. After developing EATRIS and its platforms as it is today his prime interest is to match (industry) clients with our infrastructure experts in the most efficient way to start new public-private collaborations.



Corné Baatenburg de Jong, ReumaNederland Adjunct Director

After studying business economics and social sciences at the University of Utrecht, I worked for many years in the field of organizational management. Non-profit organizations in particular have played an important role in this. For example, NOCNSF, ROC Leiden and GGZ Brabant. About 9 years ago I switched to the then Reumafonds, which is now called ReumaNederland. Within ReumaNederland I am currently responsible for both business operations and activities in the field of research financing, impact financing and osteoarthritis. Taking care with my network, networking skills, knowledge and expertise for application for citizens and patients today is my biggest motto in this area. Another important motto that characterizes me: Nothing is impossible for those who want it!



Daria Julkowska, EJP RD Scientific Coordinator

Daria Julkowska has a PhD in molecular biology and pursued her scientific vocation by the post-doctoral experience in cellular biology, at Institut Pasteur, Paris and extensive training in communication and European Union counselling. She also holds MSc in Management of Research from the University of Paris Dauphine. She is the Scientific Coordinator of the European Joint Programme on Rare Diseases (EJP RD) that brings together over 130 institutions representing different type of stakeholders (researchers, funders, clinicians & patients) from 35 countries from Europe and beyond, and is also responsible for the coordination of the IRDiRC Scientific Secretariat. She is involved in the rare diseases field since 2010. She developed and put into action a set of collaborations facilitating research, including the partnerships with European Research Infrastructures, Patients' Organisations and industry. She has an extensive knowledge and understanding of European funding schemes and programmes and serves as the chair of the Expert Group on support for the strategic coordinating process for European partnerships of the European Commission. In 2020 she received EURORDIS Black Pearls Award for the European Rare Diseases Leadership.



Cécile Ollivier, C-Path Managing Director (Europe)

Cécile is Managing Director for C-Path in Europe facilitating the development of global regulatory science strategies in high unmet needs areas in collaboration with regulatory agencies. She is a senior health engineer with over 15 years of experience in global drug development, particularly for paediatric and rare diseases. Prior to joining Critical Path Institute, Cécile was for 2 years with a medical technology company developing digital endpoints, and for 11 years a scientific officer at the European Medicines Agency (EMA). At EMA, she provided technical and regulatory expert guidance on the design, conduct and interpretation of paediatric developments across multiple therapeutic areas. Cécile has been recognised for her work leading the EMA extrapolation global strategy and activities including developing EMA/FDA harmonisation. She was also an expert in the E11 R(1) working group and the paediatric standing group for the International Conference of Harmonization (ICH). Additionally, Cécile is currently a consultant for the WHO Global Accelerator for Paediatric Formulations Network (GAP-f).



Lars Schlotawa, Consultant for paediatrics, child neurology and metabolic medicine at the University Medical Centre Goettingen

Lars Schlotawa, MD, has been working as a consultant for paediatrics, child neurology and metabolic medicine at the University Medical Centre Goettingen, Germany since 2018. He specialised in rare, neurodegenerative and neurometabolic diseases in children with special interest in Lysosomal Diseases. His research expertise comprises development of therapeutic approaches for lysosomal diseases through high-throughput drug screening and elucidation of cellular details of disease pathology and identification of druggable targets as well as clinical research including natural disease history studies and interventional trials in a truly translational approach. He is also affiliated with the Fraunhofer Institute for Translational Medicine, Germany.



Ivo G. Gut, Director of Centro Nacional de Analisis Genómico, Barcelona

Ivo G. Gut is Director of the Centro Nacional de Análisis Genómico (CNAG) based in Barcelona, one of the largest genome sequencing centres in Europe. He is principal investigator of the ongoing EU-funded projects Beyond 1 Million Genomes, 3TR, BCLL@las, EUCanCan, SCREEN4CARE, IMMUCan, EJP-RD, and participates in large international projects and consortia such as the International Cancer Genome Consortium (ICGC), the International Human Epigenome Consortium (IHEC), the International Rare Disease Research Consortium (IRDiRC) and the Human Cell Atlas (HCA). He is author of more than 400 research papers (H-index >120), 11 reviews and 12 book chapters, cited over 68 000 times, inventor of 26 patents or patent applications, founder of 4 biotech start-ups, and serves on numerous international advisory boards.



Ewa Ellis, Laboratory director of the liver cell laboratory at the unit for transplantation surgery, Karolinska Institutet; President of the Cell Transplant and Regenerative Medicine Society, under TTS

Ewa Ellis is an assistant professor in experimental gastroenterology and hepatology at Karolinska Institute. She works at the Karolinska Center for Cell Therapy as an ATMP coordinator. Ewa is also a core team member of the Innovation milieu, ATMP2030.



Alain van Gool, Professor Personalized Healthcare at the Radboud University Medical Center; EATRIS-Plus representative

Alain van Gool is professor Personalized Healthcare at the Radboud university medical center, with a strong passion in the application of biomarkers in translational medicine and personalized healthcare. After his PhD (molecular and cellular biology, 1996) Alain worked at a mix of academia, pharmaceutical industries, applied research institutes, university medical centers in Europe, Asia and USA. He has been leading technology-based biomarker laboratories, cross-functional expert teams, therapeutic project teams and public-private consortia, many of which were focused on the discovery, development and implementation of translational biomarkers in a variety of therapeutic areas. His technical expertise resides most strongly in molecular profiling (various Omics approaches), analytical biomarker development and applications in translational scientific research.



Fátima Núñez (Deputy Director of Research, Innovation and Knowledge Management at Hospital Sant Joan de Deu Barcelona)

Fátima Núñez holds a B.A. in Genetics from Trinity College Dublin, Ireland, and a Darwin Trust PhD in Molecular and Cell Biology from the University of Edinburgh (1994 - 1999). During the period 2000 - 2004 she did a postdoc at the Cancer Research Centre in

Salamanca, Spain, on signal transduction in cancer. In 2005, she started her career in science management by joining the Vall d'Hebron Research Institute (VHIR) where she held several positions, from Coordinator of the institution's Core Facilities to Deputy CEO where she performed a wide range of functions mainly focused on the design and implementation of scientific strategy and the promotion of the strategic projection and positioning of the institution. In November 2022 she became the Deputy Director of Research, Innovation and Learning at the paediatric Hospital Sant Joan de Déu Barcelona, as well as the Deputy Director of the Sant Joan de Déu Research Institute. She has been a member of the Steering Committee of the European University Hospital Alliance (EUHA). She is currently a member of the Steering Committee of the European Children's Hospitals Association (ECHO) and a member of the Scientific Advisory Board of EATRIS. She also participates in the External Scientific Committee of the Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain, and is an evaluator, among others, of the European ERA-PerMed programme.



Astrid Vicente, Head of Department of Health Promotion and NCD Prevention; Senior Researcher; Associate Professor at the Faculty of Sciences, University of Lisbon

Astrid M. Vicente is a senior researcher in biomedical sciences and public health at the National Institute of Health Doutor Ricardo Jorge, in Lisbon, Portugal, where she heads the Department of Health Promotion and Non-Communicable Disease Prevention. She is Associate Professor at the Faculty of Sciences, University of Lisbon. Her research focuses on understanding the etiology and biological processes underlying complex non-communicable diseases, with a particular interest in pathologies of the nervous system, like Autism Spectrum Disorder. She pursues a broad perspective of interactions between factors at various levels, including genomics, life style and the environment, to clarify the origins of multifactorial disorders. Astrid Vicente is currently very interested in fostering progress towards translation of knowledge into personalised strategies for diagnostics, medical care and prevention. She is very involved in the public health aspects of Personalised Medicine, particularly concerning the implementation of genomics in healthcare systems, and on strategies that promote equitable access to Personalised medicine for all. She served two consecutive terms as elected Vice-Chair of the International Consortium for Personalised Medicine (ICPerMed), and is currently a member of the Steering Board and leader of the Working Group Clinical Studies. She represents the Ministry of Health of Portugal and is a member of the Coordination Group of the European 1+Million Genomes Initiative (1+MG). Astrid Vicente is also coordinating the development of the National Strategy for Genomic Medicine in Portugal.

VENUE



The event is taking place in The Hague (or “Den Haag” if you speak Dutch), the country's administrative centre and its seat of government. Our daytime programme will take place in “Museon-Omniversum”, which is a science museum in the heart of the city. Later in the evening, we invite you to join us for a meal and entertainment at “The Kunstmuseum,” The Hague's renowned modern art museum, just a short three-minute walk away from the daytime venue.

| | |
|----------------|--|
| Address | <u>Museon-Omniversum</u> Stadhouderslaan 37 2517 HV Den Haag |
| Website | <u>https://www.museon-omniversum.nl/en/</u> |
| Email | info@museon-omniversum.nl |
| Phone | 003170 338 13 38 |

EVENT CONTACTS



Ivette Corominas, EATRIS Event Coordinator

+34 (0) 639251585

ivettecorominas@eatris.eu



Jake Fairnie, EATRIS Head of Communications

+31 (0) 652 353756

jakefairnie@eatris.eu



Piret Baur, EATRIS Communications Manager

+31 (0) 620579161

piretbaur@eatris.eu



Danielle Tonnesen, EATRIS Operations & Administrative Assistant

+31 (0) 62 54 33528

danielletonnesen@eatris.eu



eatris.eu



linkedin.com/company/eatris-eric



twitter.com/EatrisEric



youtube.com/c/EATRIS-ERIC



facebook.com/EATRIS.ERIC